Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Functional and Neurochemical Brain Changes Following Successful Treatment of Early Course Bipolar Depression
This study is currently recruiting participants.
Verified by University of Cincinnati, July 2008
Sponsored by: University of Cincinnati
Information provided by: University of Cincinnati
ClinicalTrials.gov Identifier: NCT00608296
  Purpose

The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving quetiapine or lithium, in order to better understand who benefits from treatment and why they respond to medications.


Condition
Bipolar

MedlinePlus related topics: Depression
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective

Further study details as provided by University of Cincinnati:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 120
Study Start Date: January 2008
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Study subjects on lithium
2
study subjects on quetiapine
3
healthy control

  Eligibility

Ages Eligible for Study:   16 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

You are being asked to take part in this research study because you have been diagnosed with bipolar disorder and are currently experiencing a depressive episode. Bipolar disorder is an illness characterized by recurrent mood swings including mania, (periods of elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless behavior) and clinical depression (periods of depressed mood, loss of interest in activities and disruption of sleep, appetite and energy). To participate in this study you must be at least 16 years old, and no older than 35.

Criteria

Inclusion Criteria - Depressed bipolar patients (N=80; 15-20 patients/year):

  1. Patients will meet DSM-IV criteria for type I bipolar disorder, depressed, as determined by structured interview and best-estimate diagnostic procedures.138
  2. Patients will have no history of any Axis I psychiatric disorder except for bipolar disorder.
  3. Patient has experienced a maximum of three documented affective episodes.
  4. Patient has been off medications for ≥ two weeks (or five half-lives, whichever is longer) prior to study enrollment.
  5. Patient has a Hamilton Depression Rating Scale (HDRS) total score ≥20 and a Young Mania Rating Scale (YMRS) total score ≤12.140,141,160
  6. Patient is between the ages of 16 and 35 years.

Inclusion Criteria - Healthy subjects (N=40; 8-10 subjects/year):

  1. Healthy subjects will be between the ages of 16 and 35 years.
  2. Healthy subjects will have no history of any Axis I psychiatric disorder.
  3. Healthy subjects will have no first- or second-degree relatives with affective or psychotic disorders.

Exclusion criteria: All subjects will be excluded from participation for the following reasons:

  1. Any history of alcohol or drug dependence, and any alcohol or drug use disorder within 3 months.
  2. Any history of significant suicidality that would place the patient at risk to participate in this protocol.
  3. Current score ≥3 on item 3 of the HDRS-17 (Suicide Item)
  4. Any medical or neurological disorder that could influence fMRI results.
  5. A history of mental retardation or an estimated IQ total score <85.
  6. An MRI scan is contraindicated in the subject for any reason.
  7. The patient lives >100 miles from the University of Cincinnati or cannot attend follow-up visits.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00608296

Contacts
Contact: Jonathon Schroer, BA, BPh 513-558-3991 jonathon.schroer@uc.edu

Locations
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267-0559
Sponsors and Collaborators
University of Cincinnati
Investigators
Principal Investigator: Caleb M Adler, MD University of Cincinnati
  More Information

Responsible Party: University of Cincinnati ( Caleb M. Adler, MD )
Study ID Numbers: BITREC - Project II
Study First Received: January 23, 2008
Last Updated: July 21, 2008
ClinicalTrials.gov Identifier: NCT00608296  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Depression
Depressive Disorder

ClinicalTrials.gov processed this record on January 16, 2009